Guidelines for Crimean-Congo Hemorrhagic Fever (CCHF)

Objectives

The material focuses on reducing transmission and mortality from Crimean-Congo haemorrhagic fever (CCHF), particularly healthcare-associated transmission, through early recognition and isolation of probable or confirmed cases, supportive clinical management, careful use of ribavirin, protection of exposed people, and measures to reduce contact with infected ticks, animals, blood, secretions and deceased persons.[1][2][3]The excerpts do not set out a wider mission statement, quantified targets or a formal strategic framework.[3][4]

• Prevent nosocomial transmission through separate patient accommodation, barrier nursing, decontamination, safe management of sharps and infectious materials, and controlled handling of laboratory specimens.[1][3]
• Reduce community and occupational exposure by educating the public, promoting protective clothing and repellents, supporting acaricide-based tick control in livestock settings, and protecting livestock workers.[2]
• Protect contacts of infected animals and patients through exposure assessment, clinical observation, baseline testing and targeted treatment or prophylaxis decisions under physician supervision.[2][4]
• Ensure safe management of deceased persons through procedures involving disinfection, bleach, sealed wrapping and precautions during burial.[2]
• Support clinical care with intensive monitoring to guide fluid and blood-component replacement, alongside oral ribavirin for probable cases in consultation with the attending physician.[1]

Implementation

Implementation is centred on hospital infection prevention and control, clinically supervised case and contact management, laboratory biosafety, and public-health communication. Patients who are probable or confirmed CCHF cases are to be isolated and cared for under strict barrier-nursing arrangements, while hospitals are expected to maintain supplies of ribavirin, identified in Pakistan as Ribazole®.[1][2][3]The excerpts identify designated healthcare staff, attending physicians, supervisors and laboratories as operational actors, but do not specify a formal governance structure, coordination mechanism, delivery timetable or implementation budget.[3][4]

• Manage patients in separate rooms with designated medical and paramedical staff and attendants, using disposable personal protective equipment and strict barriers against exposure to blood and body fluids.[1][3]
• Dispose of sharps safely; decontaminate clinical surfaces; autoclave or incinerate contaminated materials; and fumigate relevant areas after patient discharge.[1][3]
• Provide supportive therapy and intensive clinical monitoring to determine requirements for volume replacement and blood components.[1]
• Use physician oversight for ribavirin decisions, including treatment of probable cases and management of people with direct accidental exposure to blood or secretions; provide advice on adverse effects and pregnancy prevention where relevant.[1][4]
• Classify and follow contacts including people exposed to the same animals, household and other patient contacts, healthcare workers, and people with needle-stick injuries or comparable exposure to blood or secretions.[4]
• Monitor contacts without clear-cut direct exposure for up to 14 days after their last exposure, including twice-daily temperature recording and baseline blood studies.[2][4]
• Initiate further clinical action when monitored contacts become clearly ill, with fever of at least 38.5 °C together with headache or myalgia; reserve confirmatory blood testing during observation for contacts who develop these symptoms.[2][4]
• Collect, label, seal and externally decontaminate specimens; use triple packaging; notify the designated laboratory; and transport samples cautiously to avoid breakage and spills.[3]
• Educate communities on CCHF transmission and personal protection, while supporting tick-control measures in livestock facilities and safer burial practice.[2]
• Maintain ribavirin stocks in hospitals, although no costs, funding source, resource-mobilisation plan or detailed financing arrangements are specified.[2][3]

Monitoring & Evaluation

Monitoring centres on clinical observation of patients and time-limited follow-up of people exposed to Crimean-Congo haemorrhagic fever (CCHF), rather than on a formal programme-wide evaluation system. Intensive clinical monitoring is used to guide replacement of fluids and blood components in probable cases.[1]Contacts are monitored for up to 14 days after their last exposure, with temperature recorded twice daily.[2][4]

• Monitor household contacts, people exposed to the same animals, other patient contacts and exposed healthcare workers for symptoms during the observation period.[4]
• Measure temperature twice daily and undertake baseline blood studies for contacts, as specified in the exposure-management protocol.[2][4]
• Identify a contact as a probable case when fever of at least 38.5 °C occurs with headache and muscle pain or myalgia, then arrange hospital admission and clinical management including ribavirin as indicated.[2][4]
• Reserve confirmatory blood testing during observation for contacts who become definitely ill with fever, headache and myalgia; consider testing after 14 days for research on sub-clinical infection.[4]
• Apply baseline testing and physician-supervised prophylactic ribavirin for people with clear accidental exposure to blood or secretions, while treating other contacts with ribavirin only if they develop genuine illness.[2][4]
• Use clinical supervision, designated staff, isolation procedures and laboratory notification as operational controls for case management, exposure management and safe specimen handling.[3][4]

The available text does not specify population-level surveillance arrangements, notification pathways, routine reporting formats, data-management systems, performance indicators, targets, evaluation schedules, audit procedures or formal accountability mechanisms.[1][2][3][4]

Costing & Financing

Resource requirements are identified mainly in operational terms. Hospitals are expected to maintain stocks of ribavirin, identified in Pakistan as Ribazole®, alongside the supplies and infrastructure required for isolation, barrier nursing, personal protective equipment, decontamination, safe disposal and laboratory specimen transport.[2][3]No monetary costing or financing framework is provided.[3][4]

• Maintain hospital stocks of ribavirin for probable cases and exposure prophylaxis under physician supervision.[2][3][4]
• Provide resources for separate patient rooms, designated clinical and paramedical staff, disposable protective equipment, safe sharps disposal, autoclaving or incineration, surface disinfection and fumigation.[3]
• Support safe sample handling through labelled and sealed containers, external decontamination, triple packaging, prior laboratory notification and cautious transport.[3]
• Support prevention measures including public education, acaricide-based tick control in livestock facilities, protective clothing, repellents and safe burial materials and disinfection procedures.[2]

The text does not specify prices, budget allocations, funding sources, donor contributions, resource-mobilisation arrangements, funding gaps, costing methods, affordability assessments or economic assumptions.[1][2][3][4]